Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN3500 MAD study in moderate asthma
NCT02999711Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of itepekimab in asthma (2 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of treatment emergent adverse events up to 36 weeks and Severity of treatment emergent adverse events up to 36 weeks. Started Feb 2017; status: completed.
02
Drugs
itepekimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02999711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999711.